European Association for Haemophilia and Allied Disorders (EAHAD)
Octapharma is thrilled to participate in the 14th annual congress of the European Association for Haemophilia and Allied Disorders, EAHAD 2021 from 3 - 5 February 2021, with the satellite symposium:
“A family journey with Nuwiq® (simoctocog alfa): Early treatment decisions for long-term health”
The session is chaired by Dr Robert F. Sidonio Jr. (Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Children’s Healthcare of Atlanta, Emory University, Atlanta, USA) and follows the treatment journey of a family with two sons diagnosed with severe haemophilia A.
Speakers address key treatment decisions and considerations for long-term health, including prevention and treatment of bleeds, inhibitor risk, inhibitor eradication, and bone and joint health in the context of the evolving haemophilia A treatment landscape.
The symposium was live via the EAHAD online platform on Thursday, February 4 (2021), at 18:00 CET. It is now available on demand.
"We are proud to share real-life experience of the positive impact of Nuwiq® in children with haemophilia A. Alongside clinical trial data across our portfolio, such experience helps to inform treatment decisions, which are increasingly complex as new therapies arise.” Larisa Belyanskaya, Head of IBU Haematology, Octapharma
“Our ultimate aim at Octapharma is to improve patients’ lives, and seeing our work achieve this goal brings real pride. Our contributions to the EAHAD congress highlight our commitment to enabling people with haemophilia A to lead a long, active and healthy life”. Olaf Walter, Board Member , Octapharma
We also invite you to a poster session with Dr Silvia Horneff (Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany), who will present single-centre experience of bleeding management in 46 patients with acquired haemophilia A, a rare autoimmune disorder:
Poster ABS193, Safety and efficacy of high-dose, plasma-derived FVIII in patients with acquired haemophilia A (Di Prinzio G et al.)
Octapharma participates at the 14th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), with a satellite symposium and poster presentation.
Please note that only healthcare professionals are allowed to watch the sessions.